2016年IgA肾病牛津分类:IgA肾病分类工作组更新
本文是IgA肾病分类工作组的更新。在至少8个肾小球的活检标本中,M、S、T病变可预测临床结局;在更大队列中新月体(C)可预测结局,故推荐将C加入MEST评分并报告MEST-C评分。E病变仅在未接受免疫抑制者中预测结局;MEST评分联合活检时临床数据与监测2年临床数据预测效能相同。
要点
- 推荐将新月体(C)加入MEST评分,活检报告应提供MEST-C评分
- M、S、T病变在至少8个肾小球的标本中预测临床结局
- MEST评分联合活检时临床数据与监测2年临床数据预测效能相同
核心结论
- 在至少8个肾小球的活检标本中,M、S、T病变可预测临床结局,新月体(C)可预测结局,推荐将C加入MEST评分并报告MEST-C评分。
研究设计与样本
- 本文为IgA肾病分类工作组的更新,基于进一步回顾性队列研究及更大、更广泛队列的分析。
主要发现
- E病变在儿童和成人中预测结局,但仅在未接受免疫抑制者中如此。
- 对S病变的综述提示,对节段性硬化进行亚分类、识别有足细胞损伤证据的病例可能具有临床实用性。
- MEST评分联合活检时临床数据与监测2年临床数据具有相同预测效能,此需进一步评估以评价早期有效治疗干预。
- 已建立来自成人和儿童IgA肾病大型队列的特征明确数据集,为完善风险预测和临床实用性的进一步研究提供基础,包括MEST-C评分及其他因素。
关键数值与推荐
- 活检报告应提供MEST-C评分,即在MEST基础上加入新月体(C)。
- M、S、T病变的预测价值基于至少8个肾小球的活检标本。
- E病变的预测价值仅见于未接受免疫抑制的儿童和成人。
临床怎么用
- 作者建议将新月体(C)加入MEST评分,活检报告应提供MEST-C评分,并已开发基于网络的教育工具协助病理医师报告M和E病变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the Oxford Classification of IgA nephropathy (IgAN) was published in 2009, MEST scores have been increasingly used in clinical practice. Further retrospective cohort studies have confirmed that in biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions predict clinical outcome. In a larger, more broadly based cohort than in the original Oxford study, crescents (C) are predictive of outcome, and we now recommend that C be added to the MEST score, and biopsy reporting should provide a MEST-C score. Inconsistencies in the reporting of M and endocapillary cellularity (E) lesions have been reported, so a web-based educational tool to assist pathologists has been developed. A large study showed E lesions are predictive of outcome in children and adults, but only in those without immunosuppression. A review of S lesions suggests there may be clinical utility in the subclassification of segmental sclerosis, identifying those cases with evidence of podocyte damage. It has now been shown that combining the MEST score with clinical data at biopsy provides the same predictive power as monitoring clinical data for 2 years; this requires further evaluation to assess earlier effective treatment intervention. The IgAN Classification Working Group has established a well-characterized dataset from a large cohort of adults and children with IgAN that will provide a substrate for further studies to refine risk prediction and clinical utility, including the MEST-C score and other factors.
引用
- Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017. PMID: 28341274. doi:10.1016/j.kint.2017.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。